CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. - Wasan, H. S.; Springett, G. M.; Chodkiewicz, C.; Wong, R.; Maurel, J.; Barone, C.; Rosbrook, B.; Ricart, A. D.; Kim, S.; Spano, J.-P. (British Journal of Cancer, 2009)